The SF -6D Brazil: Construction models and applic ations in health economics;O questionário SF-6D Brasil: Modelos de construção e aplic ações em economi a da saúde

Revista da Associacao Medica Brasileira

Volumn 56, Issue 4, 2010, Pages 409-414

  Campolina, Alessandro Gonçalves ^a   Bortoluzzo, Adriana Bruscato ^a,b   Ferraz, Marcos Bosi ^a   Ciconelli, Rozana Mesquita ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSPER INSTITUTE OF EDUCATION AND RESEARCH   (Brazil)

Author keywords

Arthritis, Rheumatoid; Quality of life; Quality adjusted life years

Indexed keywords

EID: 77957748326     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0104-42302010000400012     Document Type: Article

References (37)

1. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of healthrelated quality of life measures: literature review and proposed guidelines. J Clin Epidemiol. 1993;46:1417-1432.
2. Revicki DA. Relationship of pharmacoeconomics and health-related quality of life. In: Spilker B, editor. Quality of life and paharmacoeconomics in clinical trials. Philadelphia (USA): Lippincott-Raven Publishers; 1996. p.1077-1083.
3. Nichol MB, Sengupta N, Globe DR. Evaluating quality-adjusted life years: estimation of the health utility index (HUI2) from the SF-36. Med Decis Making. 2001;21:105-112.
4. Torrance GW. Social preferences for health states: an empirical evaluation of three measurement techniques. Socioecon Plan Sci.1976;10:128-136.
5. Kaplan R M, Bush J W, Berry C. Health status: Types of validity and the index of well-being. Health Serv Res. 1976;11:478-507.
6. Torrance GW. Designing and conducting cost-utility analyses. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia (USA): Lippincott-Raven Publishers; 1996. p.1105-1111.
7. Doctor JN, Bleichrodt H, Miyamoto J, et al. A new and more robust test of QALYs. J Health Econom. 2004;23:353-367.
8. Torrance GW, Feeny DH. Utilities and Quality-Adjusted Life Years. Int J Technol Assess Health Care. 1989;5:559-575.
9. Prieto L, Sacristán JA. Problems and solutions in calculating quality-adjusted life years (QALY's). Health Quality Life Outcomes 2003;1:80.
10. Torrance GW, Furlong W, Feeny D. Health utility estimation. Expert Rev Pharmacoecon Outcomes Res.2002;2:99-108.
11. Ware JE, Sherbourne CD. The MOS 36-item short health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
12. Garrat AM, Schmidt L, Mackintosh A, Fitzpatrick R. Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ. 2002;324:1417-1421.
13. Lee TA, Hollingworth W, Sullivan SD. Comparison of directly elicited preference to preferences derived from the SF-36 in adults with asthma. Med Decis Making. 2003;23:323-334.
14. Hollingworth W, Deyo RA, Sullivan SD, Emerson SS, Gray DT, Jarvik LG. The practicality and validity of directly elicited and SF-36 derived health state preferences in patients with low back pain. Health Econ. 2002;11:71-85.
15. Sherbourne CD, Unutzer J, Schoenbaum M, Schoenbaum M, Duan N, Lenert LA, et al. Can utility-weighted health-related quality-of-life estimates capture heath effects of quality improvement for depression? Med Care. 2001;39:1246-1259.
16. Lobo ES, Gross CR, Matthees BJ. Estimation and comparison of derived preference scores from the SF-36 in lung transplant patients. Qual Life Res. 2004;13:377-379.
17. Maor Y, King M, Olmer L, Mozes B. A comparison of three measures: the time trade-off technique, global heath related quality of Life and the SF-36 in dialysis patients. J Clin Epidemiol. 2001;54:565-570.
18. Thein HH, Krahn M, Kaldor JM, Dore GJ. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol. 2005;100:643-651.
19. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol. 1998;51:1115-1128.
20. Brazier JB, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21:271-292.
21. Gonçalves Campolina A, Bruscato Bortoluzzo A, Bosi Ferraz M, Mesquita Ciconelli R. Validity of the SF-6D index in Brazilian patients with rheumatoid arthritis. Clin Exp Rheumatol. 2009;27:237-245.
22. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
23. Ciconelli RM, Ferraz MB, Santos W, Meinão I, Quaresma MR. Tradução para a língua portuguesa e validação do questionário genérico de avaliação de qualidade de vida SF-36 (Brasil SF-36). Rev Bras Reumatol. 1999;39:143-150.
24. Wolfe F, Kleinheksel SM, Cathey MA, Hawley DJ, Spitz PW, Fries JF. The clinical value of the Stanford Health Assessment Questionnaire functional disability index in patients with rheumatoid arthritis. J Rheumatol. 1988;15:1480-1488.
25. Kind P. The performance characteristics of EQ-5D, a measure of health related quality of life for use in technology assessment. In: 13 Annual Meeting of International Society of Technology Assessment in Health Care 1997. p.81. Abstract.
26. Dolan P. Modeling valuations for Euroqol Health States. Med Care. 1997;35:1095-1108.
27. Kaplan RM, Groessl EJ, Sengupta N, Sieber WJ, Ganiats TG. Comparison of measure utility scores and imputed scores from the SF-36 in patients with rheumatoid arthritis. Med Care. 2005;43:79-87.
28. Longworth L, Bryan S. An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ. 2003;12:1061-1067.
29. O' Brien BJ, Spath M, Blackhouse G, Severens JL, Dorian P, Brazier P. A view from the bridge: agreement between the SF-6D utility algorithm and the Health Utilities Index. Health Econ. 2003;12:975-981.
30. Conner-Spady B, Suarez-Almazor ME. Variation in the estimation of qualityadjusted life-years by different preference-based instruments. Med Care. 2003;41:791-801.
31. De Wit GA, Busschbach JJ, De Charro FT. Sensitivity and perspective in the valuation o health status: whose values count? Health Econ. 2000;9:109-126.
32. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel of cost-effectiveness in health and medicine. JAMA. 1996;276:1253-1258.
33. Emery P, Kosinski M, Li T, Williams GR, Becker JC, Blaisdell B, et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J Rheumatol. 2006;33:681-689.
34. Heiberg MS, Nordvag BY, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, et al. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six month, longitudinal, observational, multicenter study. Arthritis Rheum. 2005;52:2506-2512.
35. Teng YK, Verburg RJ, Sont JK, Van den Hout WB, Breedveld FC, Van Laar JM. Long-term follow up of health status in patients with severe rheumatoid arthritis after high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation. Arthritis Rheum. 2005;52: 2272-2276.
36. Van den Hout WB, de Jong Z, Munneke M, Hazes JM, Breedveld FC. Arthritis Rheum. 2005;53:39-47.
37. Russell AS, Conner-Spady B, Mintz A, Maksmymowych WP. The responsiveness of generic health status measures as assessed in patients with rheumatoid arthritis receiving infliximab. J Rheumatol. 2003;30:941-947.